Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455578 | 1.00 | CYP4F2 (0.54) | CYP4F2CYP4A11MRGPRX4TP53PKM | |
| SCHEMBL18105889 | 0.91 | CYP4F2 (0.58) | CYP4F2CYP4A11MRGPRX4TP53PKM | |
| SCHEMBL4339720 | 0.88 | CYP4F2 (0.54) | CYP4F2CYP4A11TDP1MAPTRAB9A | |
| SCHEMBL4425984 | 0.87 | CYP4F2 (0.64) | CYP4F2CYP4A11TDP1ALOX5ALDH1A1 | |
| SCHEMBL31455819 | 0.84 | CYP4F2 (0.54) | CYP4F2CYP4A11MRGPRX4TP53PKM | |
| SCHEMBL3530979 | 0.84 | CYP4F2 (0.54) | CYP4F2CYP4A11MRGPRX4TP53PKM | |
| SCHEMBL3060348 | 0.84 | MRGPRX4 (0.56) | CYP4F2CYP4A11MRGPRX4TP53PKM | |
| SCHEMBL3175580 | 0.84 | CYP4F2 (0.57) | CYP4F2CYP4A11TDP1ALOX5 | |
| SCHEMBL10508352 | 0.83 | CYP4F2 (0.49) | CYP4F2CYP4A11TDP1MAPTRAB9A | |
| SCHEMBL9444564 | 0.83 | CYP4F2 (0.63) | CYP4F2CYP4A11SMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113582911-B | Multi-target donepezil-hydroxamic acid compound, and preparation method and application thereof | 山东大学 | 2024-03-12 | — | — | CN | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| CN-113582911-A | Multi-target donepezil-hydroxamic acid type compound and preparation method and application thereof | 山东大学 | 2021-11-02 | — | — | CN | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-02-07 | — | — | US | disclosed |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| CN-101087605-A | Medicine for treating or preventing fibrotic diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-12-12 | — | — | CN | disclosed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1318403-C | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-05-30 | — | — | CN | disclosed |
| US-7169936-B2 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ROTH GERALD J | 2007-01-04 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
| CN-1668589-A | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-14 | — | — | CN | disclosed |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, EGFR | CYP4F2 2233/4885CYP4A11 1387/4885MRGPRX4 1157/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | CYP4F2 480/4885CYP4A11 381/4885MRGPRX4 546/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | CYP4F2 480/4885CYP4A11 381/4885MRGPRX4 546/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | CYP4F2 774/4885CYP4A11 374/4885MRGPRX4 1582/4885 |
| US-20050043389-A1 | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | KDR, FLT1, EGFR | CYP4F2 2233/4885CYP4A11 1387/4885MRGPRX4 1157/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | CYP4F2 483/4885CYP4A11 412/4885MRGPRX4 567/4885 |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | MMP1, COL1A1, FOXM1 | CYP4F2 480/4885CYP4A11 381/4885MRGPRX4 546/4885 |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | MMP1, COL1A1, IDO1 | CYP4F2 810/4885CYP4A11 525/4885MRGPRX4 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.